

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 23, 2002, 14:38:33 ; Search time 29.8 Seconds
(without alignments)
697.007 Million cell updates/sec

Title: US-09-811-118-1

Perfect score: 187

Sequence: 1 MVAATVAAAWLLMAAACAAQ.....VRLQITAVRKLLIKREDL 187

Scoring table:
OLIGO
Gapex 60.0, Gapext 60.0

Searched: 747574 seqs, 111073796 residues

Word size: 0

Total number of hits satisfying chosen parameters: 747574

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database: A_Geneseq_032802.*

1: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1980.DAT:*
2: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1981.DAT:*
3: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1982.DAT:*
4: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1983.DAT:*
5: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1984.DAT:*
6: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1985.DAT:*
7: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1986.DAT:*
8: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1987.DAT:*
9: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1988.DAT:*
10: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1989.DAT:*
11: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1990.DAT:*
12: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1991.DAT:*
13: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1992.DAT:*
14: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1993.DAT:*
15: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1994.DAT:*
16: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1995.DAT:*
17: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1996.DAT:*
18: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1997.DAT:*
19: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1998.DAT:*
20: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA1999.DAT:*
21: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA2000.DAT:*
22: /SIDSI/gcgdata/hold-geneseq/geneeqp-emb1/AA2001.DAT:*

Pred. NO. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	187	100.0	187	22	Human glutathione
2	104	55.6	187	21	Membrane-bound pro
3	104	55.6	187	22	Human PRO polypept
4	104	55.6	187	22	Human PRO polypept
5	104	55.6	187	22	Human protein sequ
6	104	55.6	187	22	Human secreted pro
7	104	55.6	187	22	Human PRO828 (UNO4
8	104	55.6	195	22	Human polypeptide
9	104	55.6	196	21	Human colon cancer
10	19	10.2	19	22	Human secreted pro
11	10	5.3	149	21	Human 5' EST relat

12	10	5.3	209	21	AA18915
13	10	5.3	209	21	AA24484
14	10	5.3	209	21	AA29258
15	10	5.3	209	22	AA39735
16	10	5.3	217	22	AA41521
17	9	4.8	82	21	AA612348
18	9	4.8	108	21	AA624452
19	9	4.8	116	21	AA626942
20	9	4.8	117	21	AA616585
21	9	4.8	124	21	AA63426
22	9	4.8	125	21	AA625034
23	9	4.8	156	21	AA612346
24	9	4.8	160	21	AA626941
25	9	4.8	166	22	AA604502
26	9	4.8	166	22	AA604503
27	9	4.8	166	22	AA604504
28	9	4.8	166	22	AA604505
29	9	4.8	166	22	AA604506
30	9	4.8	167	22	AA625033
31	9	4.8	167	22	AA604397
32	9	4.8	167	22	AA604398
33	9	4.8	167	22	AA604399
34	9	4.8	167	22	AA604400
35	9	4.8	167	22	AA604501
36	9	4.8	167	22	AA604515
37	9	4.8	167	22	AA604516
38	9	4.8	167	22	AA604517
39	9	4.8	167	22	AA604518
40	9	4.8	167	22	AA604519
41	9	4.8	169	21	AA644988
42	9	4.8	169	21	AA619335
43	9	4.8	169	21	AA620980
44	9	4.8	169	21	AA623532
45	9	4.8	169	21	AA642765

ALIGNMENTS

RESULT 1	
ID	AA65575 standard; Protein; 187 AA.
AC	AA65575;
XX	
DT	29-OCT-2001 (first entry)
XX	
DE	Human glutathione peroxidase (GPx6) polypeptide.
XX	
KW	Glutathione peroxidase; GPx6; anti-human immunodeficiency virus; HIV;
KW	antifluamatory; antiallergic; antiaesthetic; antiatherosclerotic;
KW	antigenic; antihypertensive; immunosuppressive; antidiabetic; nephropoic;
KW	antigout; neuroprotective; osteoparctic; antineumatic; antianthratic;
KW	tranquillizer; vulnerary; antiatherosclerotic; hepatotropic; human;
KW	antipsoptic; cyostatic.
XX	
OS	Homo sapiens.
XX	
PN	US6231853-B1.
PD	15-MAY-2001.
XX	
PF	01-JUN-1998; 98US-0088549.
XX	
PR	01-JUN-1998; 98US-0088549.
XX	
PA	(INCYTE) INCYTE PHARM INC.
XX	
PI	Hillman JL, Corley NC, Patterson C;
XX	
DR	WPI, 2001-335067/35.
DR	N-PSDB; AA646980.
XX	

A novel polypeptid
Human secreted pro
Human PRO polypept
Human polypeptide
Human polypeptide
Zea mays protein f
Zea mays protein f
Zea mays protein f
Arabidopsis thalia
Human cancer assoc
Arabidopsis thalia
Zea mays protein f
Zea mays protein f
Orange strisec mut
Orange strisec mut
Alce arborescens S
Alce vera strisec m
Synthetic str2 mute
Arabidopsis thalia
Orange phospholipi
Alce arborescens P
Alce arborescens P
Alce vera PHGPX en
Orange PHGPX/Clt-S
Alce vera PHGPX en
Alce arborescens P
Alce arborescens P
Alce vera PHGPX mu
Glutathione peroxi
Arabidopsis thalia
Arabidopsis thalia
Arabidopsis thalia

PT New substantially purified human glutathione peroxidase polypeptide,
PT useful for diagnosing, treating or preventing reproductive disorders,
PT immune disorders and cell proliferative or developmental disorders -
XX

Claim 1; Fig 1A-C; 26pp; English.

Claim 1; Fig 1A-C; 26pp; English.

CC *mus* represents a human glutathione peroxidase (Gpx6) polypeptide. The
CC Gpx6 polypeptide is useful for diagnosing, treating or preventing
CC disorders associated with expression of Gpx6, where the disorders are
CC selected from reproductive disorders, immune disorders such as acquired
CC immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory
CC distress syndrome, allergies, asthma, atherosclerosis, anemia, autoimmune
CC thyroiditis, bronchitis, diabetes mellitus, glomerulonephritis,
CC Goodpasture's syndrome, gout, multiple sclerosis, myasthenia gravis,
CC osteoporosis, rheumatoid arthritis, cancer, infections and trauma, and
CC cell proliferative or developmental disorders such as arteriosclerosis,
CC cirrhosis, psoriasis, cancer, Cushing's syndrome, and Sydenham's chorea.
CC Gpx6 is also useful to produce antibodies, and to screen libraries of
CC pharmaceutical agents to identify those which specifically binds Gpx6.
XX

SQ Sequence 187 AA;

Query Match	100.0%	Score 187;	DB 22;	Length 187;
Best Local Similarity	100.0%	Pred. No. 7.3e-187;		
Matches 187; Conservative	0;	Mismatches 0;	Indels 0;	Gaps 0

QY	1	MAATVAANAATLLAAACAAOEOEDFYOPFKANNIGKLYLSELEKRGSVSLVYVNAASEGFT	60
Db	1	mvaatvaanaaalllwaacaacqgqdfydfikavnllgklylslekrgsvslvynnaasegft	60
QY	61	DOHRYALQOOLORDLGCPHHFNVLAPPCNOFGOEPDSNKEIESFACRYSVSFPMESKIAV	120
Db	61	dghryalrqqlrdldgphhfnvlnafpcnqfqqgqedsnkeiesfacrlysvsfpmfisklav	120
QY	121	TGTGAAHFAEYRYLAOTSKEPTMWFMYLVAADGKRVGAMPDPTVSEVEEVRQITALVYKLI	180
Db	121	tgtgcahpaefyrlaqtsqkeptwfmkylvpadpdkrvvgawapdvsvveevrlqitaltalvklil	180
QY	181	LTKREDL 187	
Db	181	lltkredl 187	

RESULT	2
AAV66677	
ID	AAV66677 standard; protein; 187 AA

AC AAY66677;

DT 05-APR-2000 (first entry)
 YY

DE Membrane-bound protein PRO828.

pharmaceutical; receptor immunoadhesin; gene mapping.

Homo sapiens.

PN W09963088-A2.

PD 09-DEC-1999.

02-JUN-1999; 99WO-US12252

02-JUN-1998; 98US-00876

02-JUN-1998; 98US-00877

04-JUN-1998; 98US-008802

[illegible]

04-JUN-1998; 98US-008802

PR	04-JUN-1998;	98US-0088033
PR	04-JUN-1998;	98US-0088326
PR	05-JUN-1998;	98US-0088167
PR	05-JUN-1998;	98US-0088302
PR	05-JUN-1998;	98US-0088212
PR	05-JUN-1998;	98US-0088217
PR	09-JUN-1998;	98US-0088655
PR	10-JUN-1998;	98US-0088722
PR	10-JUN-1998;	98US-0088730
PR	10-JUN-1998;	98US-0088738
PR	10-JUN-1998;	98US-0088811
PR	10-JUN-1998;	98US-0088824
PR	10-JUN-1998;	98US-0088825
PR	10-JUN-1998;	98US-0088858
PR	11-JUN-1998;	98US-0088861
PR	11-JUN-1998;	98US-0088863
PR	11-JUN-1998;	98US-0088876
PR	12-JUN-1998;	98US-0089090
PR	12-JUN-1998;	98US-0089105
PR	16-JUN-1998;	98US-0089440
PR	16-JUN-1998;	98US-0089512
PR	16-JUN-1998;	98US-0089514
PR	17-JUN-1998;	98US-0089531
PR	17-JUN-1998;	98US-0089536
PR	17-JUN-1998;	98US-0089598
PR	17-JUN-1998;	98US-0089599
PR	17-JUN-1998;	98US-0089600
PR	17-JUN-1998;	98US-0089653
PR	18-JUN-1998;	98US-0089801
PR	18-JUN-1998;	98US-0089907
PR	18-JUN-1998;	98US-0089908
PR	19-JUN-1998;	98US-0089947
PR	19-JUN-1998;	98US-0089948
PR	19-JUN-1998;	98US-0089952
PR	19-JUN-1998;	98US-0090246
PR	22-JUN-1998;	98US-0090252
PR	22-JUN-1998;	98US-0090254
PR	23-JUN-1998;	98US-0090349
PR	23-JUN-1998;	98US-0090355
PR	24-JUN-1998;	98US-0090429
PR	24-JUN-1998;	98US-0090411
PR	24-JUN-1998;	98US-0090435
PR	24-JUN-1998;	98US-0090444
PR	24-JUN-1998;	98US-0090445
PR	24-JUN-1998;	98US-0090461
PR	24-JUN-1998;	98US-0090472
PR	24-JUN-1998;	98US-0090535
PR	24-JUN-1998;	98US-0090538
PR	24-JUN-1998;	98US-0090540
PR	25-JUN-1998;	98US-0090557
PR	25-JUN-1998;	98US-0090676
PR	25-JUN-1998;	98US-0090678
PR	25-JUN-1998;	98US-0090688
PR	25-JUN-1998;	98US-0090690
PR	25-JUN-1998;	98US-0090691
PR	25-JUN-1998;	98US-0090694
PR	25-JUN-1998;	98US-0090695
PR	26-JUN-1998;	98US-0090696
PR	26-JUN-1998;	98US-0090692
PR	01-JUL-1998;	98US-0091358
PR	01-JUL-1998;	98US-0091360
PR	01-JUL-1998;	98US-0091344
PR	02-JUL-1998;	98US-0091478
PR	02-JUL-1998;	98US-0091519
PR	02-JUL-1998;	98US-0091519

PR 02-JUL-1998; 98US-0091626.
 PR 02-JUL-1998; 98US-0091628.
 PR 02-JUL-1998; 98US-0091633.
 PR 02-JUL-1998; 98US-0091646.
 PR 02-JUL-1998; 98US-0091673.
 PR 07-JUL-1998; 98US-0091978.
 PR 07-JUL-1998; 98US-0091982.
 PR 09-JUL-1998; 98US-0092182.
 PR 10-JUL-1998; 98US-0092372.
 PR 20-JUL-1998; 98US-0093339.
 PR 30-JUL-1998; 98US-0094651.
 PR 04-AUG-1998; 98US-0095282.
 PR 04-AUG-1998; 98US-0095285.
 PR 04-AUG-1998; 98US-0095301.
 PR 04-AUG-1998; 98US-0095302.
 PR 04-AUG-1998; 98US-0095318.
 PR 04-AUG-1998; 98US-0095321.
 PR 04-AUG-1998; 98US-0095325.
 PR 10-AUG-1998; 98US-0095916.
 PR 10-AUG-1998; 98US-0095929.
 PR 11-AUG-1998; 98US-0096012.
 PR 11-AUG-1998; 98US-0096143.
 PR 11-AUG-1998; 98US-0096146.
 PR 12-AUG-1998; 98US-0096329.
 PR 12-AUG-1998; 98US-0096357.
 PR 17-AUG-1998; 98US-0096766.
 PR 17-AUG-1998; 98US-0096768.
 PR 17-AUG-1998; 98US-0096773.
 PR 17-AUG-1998; 98US-0096791.
 PR 17-AUG-1998; 98US-0096867.
 PR 17-AUG-1998; 98US-0096891.
 PR 17-AUG-1998; 98US-0096894.
 PR 17-AUG-1998; 98US-0096895.
 PR 17-AUG-1998; 98US-0096897.
 PR 18-AUG-1998; 98US-0096949.
 PR 18-AUG-1998; 98US-0096950.
 PR 18-AUG-1998; 98US-0096959.
 PR 18-AUG-1998; 98US-0096960.
 PR 18-AUG-1998; 98US-0097022.
 PR 19-AUG-1998; 98US-0097141.
 PR 20-AUG-1998; 98US-0097218.
 PR 24-AUG-1998; 98US-0097661.
 PR 26-AUG-1998; 98US-0097951.
 PR 26-AUG-1998; 98US-0097952.
 PR 26-AUG-1998; 98US-0097954.
 PR 26-AUG-1998; 98US-0097955.
 PR 26-AUG-1998; 98US-0097971.
 PR 26-AUG-1998; 98US-0097974.
 PR 26-AUG-1998; 98US-0097978.
 PR 26-AUG-1998; 98US-0097979.
 PR 26-AUG-1998; 98US-0097986.
 PR 26-AUG-1998; 98US-0098014.
 PR 31-AUG-1998; 98US-0098525.
 PR 16-SEP-1998; 98US-0100634.
 PR 12-JAN-1999; 99US-0115565.
 PA (GETH) GENENTECH INC.
 XX Baker K, Chen J, Goddard A, Gurney AL, Smith V, Watanabe CK;
 PI Wood WI, Yuan J;
 DR WPI; 2000-072883/06.
 DR N-PSDB; AAZ65013.
 XX
 PT Membrane-bound proteins and related nucleotide sequences -
 XX
 PS claim 12; Fig 120; 822pp; English.
 CC The invention provides membrane-bound PRO polypeptides and
 CC polynucleotides encoding them. The PRO sequences of the invention were
 CC identified based on extracellular domain homology screening. The PRO
 CC sequences have homology with proteins including LDL receptors, TIE
 CC ligands and various enzymes. The membrane-bound proteins and receptor

CC molecules are useful as pharmaceutical and diagnostic agents. Receptor
 CC immunoadhesins, for instance, can be used as therapeutic agents to block
 CC receptor-ligand interactions. The membrane-bound proteins can also be
 CC employed for screening of potential peptide or small molecule inhibitors
 CC of the relevant receptor/ligand interaction. The PRO encoding sequences
 CC are useful as hybridization probes, in chromosome and gene mapping and in
 CC the generation of antisense RNA and DNA. PRO nucleic acid sequences
 CC will also be useful for the preparation of PRO polypeptides, especially
 CC by recombinant techniques.
 XX
 XX Sequence 187 AA;
 SQ
 Query Match 55.6%; Score 104; DB 21; Length 187;
 Best Local Similarity 100.0%; Pred No. 2.9e-100; Gaps 0;
 Matches 104; Conservative 0; Mismatches 0; Indels 0;
 QY 1 MVAATVAAAMLTLMAACAOQEDFYDFKAVNIRGLVLSLEKRGVSILVNVASCGFT 60
 DB 1 mvaatvaaaawlllwaacacqegqdfdfkavnlrgrlvslekrgvsvlvnvasecgtl 60
 QY 61 DQHYRALQQLQRLGPHHEVTLAFCNQGQOEPPDSNKETIESFA 104
 DB 61 dqhyralqqlqlrdlphhinvlaftpncqfqqgepsdsketesfa 104
 RESULT 3
 AAU29236
 ID AAU29236 standard; Protein; 187 AA.
 XX
 AC AAU29236;
 XX
 DT 18-DEC-2001 (first entry)
 XX
 DE Human PRO polypeptide sequence #213.
 XX
 KW PRO polypeptide; mammal; tumour; cancer; human; cattle; horse; sheep;
 KW dog; cat; pig; goat; rabbit; tumour necrosis factor alpha; TNF-alpha;
 KW blood; chondrocyte cell; cell proliferation; cell differentiation; colon;
 KW adrenal; lung; breast; prostate; rectum; cervix; liver; genetic disorder.
 OS Homo sapiens.
 XX
 PN WO200168848-A2.
 XX
 PD 20-SEP-2001.
 XX
 PF 28-FEB-2001; 2001WO-US06520.
 XX
 PR 01-MAR-2000; 2000WO-US05601.
 PR 02-MAR-2000; 2000WO-US05841.
 PR 03-MAR-2000; 2000US-187202P.
 PR 06-MAR-2000; 2000US-186968P.
 PR 14-MAR-2000; 2000US-189320P.
 PR 14-MAR-2000; 2000US-189328P.
 PR 15-MAR-2000; 2000WO-US06884.
 PR 21-MAR-2000; 2000US-190828P.
 PR 21-MAR-2000; 2000US-191007P.
 PR 21-MAR-2000; 2000US-191048P.
 PR 21-MAR-2000; 2000US-191314P.
 PR 28-MAR-2000; 2000US-192655P.
 PR 29-MAR-2000; 2000US-193032P.
 PR 29-MAR-2000; 2000US-193053P.
 PR 30-MAR-2000; 2000WO-US08439.
 PR 04-APR-2000; 2000US-194449P.
 PR 04-APR-2000; 2000US-194647P.
 PR 11-APR-2000; 2000US-195975P.
 PR 11-APR-2000; 2000US-196000P.
 PR 11-APR-2000; 2000US-196187P.
 PR 11-APR-2000; 2000US-196680P.
 PR 11-APR-2000; 2000US-196820P.
 PR 18-APR-2000; 2000US-198121P.
 PR 18-APR-2000; 2000US-198585P.

PR	25-APR-2000;	2000US-199397P.
PR	25-APR-2000;	2000US-199550P.
PR	25-APR-2000;	2000US-199654P.
PR	03-MAY-2000;	2000US-201516P.
PR	17-MAY-2000;	2000MO-US13705.
PR	22-MAY-2000;	2000MO-US14042.
PR	30-MAY-2000;	2000MO-US14941.
PR	02-JUN-2000;	2000MO-US15264.
PR	05-JUN-2000;	2000US-209832P.
PR	28-JUL-2000;	2000MO-US20710.
PR	22-AUG-2000;	2000US-0644848.
PR	24-AUG-2000;	2000MO-US23328.
PR	08-NOV-2000;	2000MO-US30952.
PR	01-DEC-2000;	2000MO-US32678.
PR	20-DEC-2000;	2000MO-US34956.
XX		
PA	(GETH) GENENTECH INC.	
PI	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL,	
PI	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;	
XX		
DR	WPI; 2001-602746/68.	
DR	N-PeSDB; AAS46137.	
XX		
PT	Novel nucleic acids encoding PRO polypeptides, used to diagnose the	
PT	presence of tumours, such as prostate and breast tumours, in mammals and	
PT	to screen for modulators of the compounds -	
XX		
PS	Claim 11; Fig 426; 774pp; English.	
XX		
CC	Sequences AAU92074-AAU92328 represent PRO polypeptides of the invention.	
CC	The PRO polypeptides and their associated nucleic acids can be used to	
CC	detect the presence of a tumour in a mammal by comparing the level of	
CC	expression of a PRO polypeptide in a test sample of cells from the animal	
CC	and a control sample of normal cells, whereby a higher level of	
CC	expression in the test sample indicates the presence of a tumour in the	
CC	mammal. Mammals include dogs, cats, cattle, horses, sheep, goats	
CC	and rabbits but are preferably human. The polypeptides can be used to	
CC	stimulate tumour necrosis factor (TNF) alpha release from human blood,	
CC	when contacted with it. A specific polypeptide can be used to stimulate	
CC	the proliferation or differentiation of chondrocyte cells. The PRO	
CC	proteins can be used to determine the presence of tumours and also	
CC	susceptibility to tumour development, particularly adrenal, lung, colon,	
CC	breast, prostate, rectal, cervical, or liver tumours, in mammalian	
CC	subjects. The oligonucleotide probes specific for the PRO nucleic acids	
CC	can be used for genetic analysis of individuals with genetic disorders.	
XX		
SQ	Sequence 187 AA;	
Query Match	55.6%; Score 104; DB 22; Length 187;	
Best Local Similarity	100.0%; Pred. No. 2.9e+100; Indels 0; Gaps 0	
Matches 104:	Conservative 0; Mismatches 0; Indels 0	
OY	1 MYAATVAAAMLMLMAAACQAQQEODFYDFKAVNIRGLIVSELEKRGSGSVSLVVNASECGET 60 	
Db	1 mwaaatvaawalllmaaacqgqgdffdfkavnlirglivalekyrgsvslvvnasecgtf 60 	
OY	61 DGHYRALQQLRDLDGFPHHNVLAFCPNQFGQGQPDSNKETIESFA 104 	
Db	61 dghyralqqlgrdlgphhnvlafpnqfyggqgepsdenketesfa 104 	
RESULT 4		
ID	AAM38871 standard; Protein: 187 AA.	
AC	AAM38871;	
XX		
DT	22-OCT-2001 (first entry)	
XX		
DE	Human polypeptide SEQ ID NO 2016.	
XX		

XX	Human; nocrotropic; immunosuppressant; cytosolic; gene therapy; cancer; peripheral nervous system; neuropathy; central nervous system; CNS;
KM	Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KM	amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KM	chemokine; thrombolytic; drug screening; arthritis; inflammation;
XX	leukaemia.
XX	
OS	Homo sapiens.
XX	
PM	WO200153312-A1.
XX	
PD	26-JUL-2001.
XX	
PF	26-DEC-2000; 2000WO-US34263.
XX	
PR	21-JAN-2000; 2000US-0488725.
XX	25-APR-2000; 2000US-0532317.
PR	09-JUL-2000; 2000US-0596042.
PR	19-JUL-2000; 2000US-0620312.
PR	03-AUG-2000; 2000US-0653450.
PR	14-SEP-2000; 2000US-0662191.
PR	19-OCT-2000; 2000US-0690306.
PR	29-NOV-2000; 2000US-0727344.
XX	
XX	(HYSE-) HYSEQ INC.
PA	
PI	Tang YF, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI	Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI	Zhao Qa, Zhou P, Goodrich R, Drmanac RT;
XX	
DR	WPI: 2001-442253/47.
XX	N-PSDB: AA158027.
XX	
PT	Novel nucleic acids and polypeptides, useful for treating disorders
PT	such as central nervous system injuries -
XX	
PS	Example 3; SEQ ID NO 2016; 10078bp; English.
XX	
XX	The invention relates to human nucleic acids (AA157798-AA161369) and
CC	the encoded polypeptides (AA138642-AA142213) with nocrotropic,
CC	immunosuppressant and cytosolic activity. The polynucleotides are useful
CC	in gene therapy. A composition containing a polypeptide or polynucleotide
CC	of the invention may be used to treat diseases of the peripheral nervous
CC	system, such as peripheral nervous injuries, peripheral neuropathy and
CC	localised neuropathies and central nervous system diseases, such as
CC	Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC	lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC	utilisation of the activities such as: immune system suppression,
CC	Activin/inhibin activity, chemotactic/chemokine activity, haemostatic
CC	and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC	assays for receptor activity, arthritis and inflammation, leukaemias and
CC	C.N.S disorders.
CC	Note: The sequence data for this patent did not form part of the printed
CC	specification.
XX	
XX	Sequence 187 AA:
SO	
Query Match	55.6%; Score 104; DB 22; Length 187;
Best Local Similarity	100.0%; Pred. No. 2.9e-100;
Matches 104; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
OY	1 MYAAATVAAAMWLLMAACACQOEODPFDFAANVIRKGLVLEKRYGSVSLVNVASCGPT 60
DB	1 MWAATVAAAWLLMAAACQGEQDIDFAVAILRGLVLEKRYGSVSLVNVASCGPT 60
OY	61 DQHYRALDOLRDLPSPHFNVLAFPCNPGCGOEPSPSNKEISFEFA 104
DB	61 dghyraldqlgrdldpshfnvnlafpcnpgcgqepdsnkkeisefa 104
RESULT	5
AAAB93154	

XX
PS Claim 12; Fig 120; 935pp; English.

CC The present invention describes human secreted and transmembrane PRO
CC proteins. The PRO proteins have cytosolic activity. The PRO proteins
CC can be used for targeted delivery of bioactive molecules, such as
CC toxins, radiolabels or antibodies, that are associated with the PRO

CC chromosomal and gene mapping, and in the generation of anti-sense RNA CC and DNA. They may also be used to produce transgenic animals which are

CC AAF44270 to AAF44470 represent PCR primers and hybridisation probes used
CC in the isolation of human PRO sequences. AAF44087 to AAF44269 and
CC AAF44270 to AAF44470 represent PCR primers and hybridisation probes used

XX Sequence 187 AA; **Sequence** of the present invention.

Quinn, M. A., & Madsen, P. (2000). *Strategic change in international markets: The case of the Japanese automobile industry*. *Academy of Management Journal*, 43, 352-376.

Matches	104;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
---------	------	--------------	----	------------	----	--------	----	------	----

Db 1 mvaatvaawallwaacagqgdlydfkavnrlgkvlslkyrgsvslvvnvasecgft 60

QY 61 DQHYRALQQLORDICPHHFVNLAFCNQFGQEPDSNKEISFA 104
|||||

Db 61 dghyralqqlrldlphhfnvlafpncnfgqgepsnkeiesfa 104

RESULT 8

AAM40657 standard; Protein; 195 AA

XX
AC
XX
AAM40657;

XX 22-OCT-2001 (first entry)

XX	Human polypeptide SEQ ID NO 5588
DE	
VV	

Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer

KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;

KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation
KW leukotriene

KW		leukaemia.
XX		
OS	Homo sapiens	

OS	Homo sapiens
XX	
PN	W0300153313-7

PN	WO200153312-A1.
XX	
PD	26-JUL-2001

PD	26-JUL-2001.
XX	
PF	26-DEC-2000. 2000WO-TS34263

PF	26-DEC-2000; 2000WO-US34263
XX	
PR	21-JAN-2000; 2000UTS-0488725

PR 21-JAN-2000; 2000US-0488725
PR 25-APR-2000; 2000US-0552317
PR 09-JUL-2000; 2000US-0588043

PR 09-JUL-2000; 2000US-0598042.
PR 19-JUL-2000; 2000US-0620312.
PR 03-AUG-2000 2000US-0653450

PR 03-AUG-2000; 2000US-0653450.
PR 14-SEP-2000; 2000US-0662191.
PR 19-OCT-2000; 2000US-0683035.

PR 19-OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.
XX

XX
PA (HYSE-) HYSEQ INC.
XX

XX Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D
PI Wang T, Wang Z, Wehrman M, Yu C, Yue J, Yuan H, Zhang L, Zhao X

PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;

XX WPI: 2001-442253/47.
DR N-PSDB: AAI59813.
XX
PT Novel nucleic acids and polypeptides, useful for treating disorders
PT such as central nervous system injuries -
XX
PS Example 2; SEQ ID NO 5588; 10078bp; English.
XX
CC The invention relates to human nucleic acids (AA157798-AA161369) and
CC the encoded polypeptides (AAM38642-AAM442213) with neurotrophic,
CC immunosuppressant and cytoskeletal activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the printed
CC specification.
XX
SQ Sequence 195 AA;
XX
Query Match 55.6%; Score 104; DB 22; Length 195;
Best Local Similarity 100.0%; Pred. No. 3e-100;
Matches 104; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 MVAATVAAAMLMLMAACACQOEODFDKAVNIRGLVSLKRYGVSIVVWVASECGT 60
DB 9 mvaatvaaaawlllwaacacagqgdlydfkavnlrgklvslkrygvsivvvascgft 68
OY 61 DGHYRALQOLRDLPHPHFNVLAFPCNPGOEPDSNKEIESFA 104
DB 69 dghyralqqlgrdlgphhfnvialfpcnpgfygqgdpnskiesfa 112
RESULT 9
AAB53468
ID AAB53468 standard; Protein; 196 AA.
XX
AC AAB53468;
XX
DT 09-MAR-2001 (first entry)
XX
DE Human colon cancer antigen protein sequence SEQ ID NO:1008.
XX
KW Human; colon cancer; colon cancer antigen; diagnosis; detection;
KW identification; cytostatic; cardioactive; neuroprotective; vulnary;
KW immunomodulatory; muscular; gynaecological; gastrointestinal;
KW neurotrophic; anti-infective; antibacterial; gene therapy; wound;
KW neural disorder; immune system disorder; muscular disorder;
KW reproductive disorder; gastrointestinal disorder; renal disorder;
KW infectious disease; cardiovascular disorder.
XX
OS Homo sapiens.
XX
PN WO200055351-A1.
XX
PD 21-SEP-2000.
XX
PF 08-MAR-2000; 2000WO-US05883.
XX
PR 12-MAR-1999; 99US-0124270.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Ruben SM;

XX WPI: 2000-587534/55.
DR N-PSDB: AAC98225.
XX
PT Colon cancer associated gene sequences, referred to as colon cancer
PT antigens, useful for the treatment, prevention, and diagnosis of colon
PT disorders such as colon cancer -
XX
PS Claim 11; Page 1592; 2104pp; English.
XX
CC AAC97991 to AAC98763 encode the human colon cancer associated proteins,
CC called human colon cancer antigens, given in AAB53234 to AAB54006. The
CC human colon cancer antigens can have cytostatic, cardioactive, muscular;
CC neuroprotective, immunomodulatory, gynaecological, gastrointestinal,
CC vulnary, nephrotoxic, anti-infective and antibacterial activities, and
CC can be used in gene therapy. The colon cancer antigen polynucleotides,
CC proteins and antibodies to the proteins are useful for the prevention,
CC treatment and diagnosis of colon disorders, such as colon cancer. The
CC polynucleotides may be used in diagnostics and research, such as for
CC chromosome identification, and as hybridisation probes. The proteins
CC may also be used to prevent diseases such as neural disorders, immune
CC system disorders, muscular disorders, reproductive disorders,
CC gastrointestinal disorders, wounds, renal disorders, infectious
CC diseases, and cardiovascular disorders. AAC98764 to AAC98772 and
CC AAB54007 represent sequences used in the exemplification of the present
CC invention.
XX
SQ Sequence 196 AA;
XX
Query Match 55.6%; Score 104; DB 21; Length 196;
Best Local Similarity 100.0%; Pred. No. 3e-100;
Matches 104; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 MVAATVAAAMLMLMAACACQOEODFDKAVNIRGLVSLKRYGVSIVVWVASECGT 60
DB 10 mvaatvaaaawlllwaacacagqgdlydfkavnlrgklvslkrygvsivvvascgft 69
OY 61 DGHYRALQOLRDLPHPHFNVLAFPCNPGOEPDSNKEIESFA 104
DB 70 dghyralqqlgrdlgphhfnvialfpcnpgfygqgdpnskiesfa 113
RESULT 10
AAB74764
ID AAB74764 standard; Protein; 19 AA.
XX
AC AAB74764;
XX
DT 12-JUN-2001 (first entry)
XX
DE Human secreted protein sequence encoded by gene 2 SEQ ID NO:73.
XX
KW Human; secreted protein; diagnosis; immunomodulatory; antisclerotic;
KW dermatological; immunosuppressive; anti-inflammatory; anti-HIV;
KW immunostimulant; cytostatic; cardiac; vascular; anti-angiogenic;
KW ophthalmological; neuroprotectant; neurotrophic; anticonvulsant; vaccine;
KW Alzheimer; antiparkinsonian; antimicrobial; vulnary; gene therapy;
KW immune disorder; hyperproliferative disorder; cardiovascular disease;
KW cancer; angiogenic disorder; neurological disorder; infectious disease;
KW wound healing; regeneration; chemotaxis.
XX
OS Homo sapiens.
XX
PN WO200112775-A2.
XX
PD 22-FEB-2001.
XX
PF 16-AUG-2000; 2000WO-US22325.
XX
PR 17-AUG-1999; 99US-0149182.
XX
PA (HUMA-) HUMAN GENOME SCI INC.

XX Rosen CA, Ni J, Florence KA, Fiscella M, Wei P, Baker KP;
 PI Birse CE, Young PE, Komatsoulis GA, Moore PA, Soppet DR;
 XX WPI; 2001-147550/15.
 DR
 XX Nucleic acids encoding 25 human secreted polypeptides, useful for
 PT preventing, diagnosing and/or treating e.g. cancers, Parkinson's
 PT disease and diabetic retinopathy -
 XX
 PS Disclosure: Page 14; 485pp; English.
 XX
 CC AAF81787 to AAF81817 encode the human secreted proteins given in AAF8174733
 CC to AAF81772. Human secreted proteins can have activities based on the
 CC tissues and cells they are expressed in. Example of activities include:
 CC immunomodulatory; antisclerotic; dermatological; immunosuppressive;
 CC antiinflammatory; anti-HIV; immunostimulant; cytostatic; cardiant;
 CC vascular; anti-angiogenic; ophthalmological; neuroprotectant; nootropic;
 CC anticonvulsant; antialzheimers; antiparkinsonian; antimicrobial; and
 CC vulnerrary. Human secreted protein nucleotide sequences (NAMI) and proteins
 CC (PEPI) may be used in the prevention, diagnosis and treatment of diseases
 CC associated with inappropriate polypeptide expression. For example, NAMI
 CC and PEPI may be used to treat disorders associated with decreased
 CC expression by rectifying mutations or deletions in a patients genome
 CC that affect the activity of proteins by expressing inactive proteins or
 CC to supplement the activity of proteins own production of polypeptides. Disorders that
 CC may be prevented, diagnosed and/or treated include immune disorders,
 CC hyperproliferative disorders (e.g. cancers), cardiovascular diseases,
 CC angiogenic disorders, neurological disorders, infectious diseases and/or
 CC for promoting wound healing, regeneration and/or chemotaxis. AAF81778 to
 CC AAF81786 and AAF81732 represent sequences used in the exemplification of
 CC the present invention.
 CC
 SQ Sequence 19 AA:
 Query Match 10.2%; Score 19; DB 22; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.9e-12;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 78 HFNVLAFPCNOFGOEPDS 96
 ||||||||||||||||
 DB 1 hfnvlaifpncgfgqgepds 19
 RESULT 11
 AAF65356
 ID AAF65356 standard; Protein; 149 AA.
 XX
 AC AAF65356;
 XX
 DT 01-FEB-2000 (first entry)
 XX
 DE Human 5' EST related polypeptide SEQ ID NO:1517.
 XX
 KW Human; 5' EST; expressed sequence tag; secreted protein; diagnosis;
 KW gene therapy; chromosome mapping; upstream regulatory sequence;
 KW forensic; location; development; protein synthesis; stability;
 KW regulation; identification.
 XX
 OS Homo sapiens.
 XX
 FN W09953051-A2.
 XX
 PD 21-OCT-1999.
 XX
 PF 09-APR-1999; 99WO-IB00712.
 XX
 PR 09-APR-1998; 98US-0057719.
 PR 28-APR-1998; 98US-0069047.
 XX
 PA (GSET) GENSET.

XX
 PI Dumas Milne Edwards J, Duclert A, Giordano J;
 XX WPI; 2000-038446/03.
 DR N-PSDB; AA242970.
 XX
 PT Novel secreted protein 5' expressed sequence tag sequences used in
 PT diagnostic, forensic, gene therapy, and chromosome mapping procedures
 XX
 PS Claim 3; Page 808; 837pp; English.
 XX
 CC AA242265 to AA243075 represent novel 5' expressed sequence tag (EST)
 CC sequences, corresponding to human secreted proteins. AAF64651 to
 CC AAF65438 represent the EST-related proteins corresponding to AA242265 to
 CC AA243052. The 5' ESTs can be used for producing secreted human gene
 CC products. They can be used to identify and isolate 5' untranslated
 CC regions (UTRs) and upstream regulatory regions which control the
 CC location, development stage, rate, and quantity of protein synthesis, as
 CC well as stability of mRNA. The ESTs are also useful as probes for
 CC chromosome mapping, and to obtain full length cDNA clones. The ESTs can
 CC also be used in forensic procedures to identify individuals, or in
 CC diagnostic procedures to identify individuals having genetic diseases
 CC resulting from abnormal gene expression. The products may also be used in
 CC gene therapy protocols. The nucleic acids encoding signal peptides can be
 CC used for directing extracellular secretion of a polypeptide or the
 CC insertion of a polypeptide into a membrane, or importing a polypeptide
 CC into a cell. The proteins encoded by the EST sequences may be useful in
 CC treating a variety of human conditions. Secreted proteins have
 CC therapeutic value, and the identification of new secreted proteins is
 CC valuable. AA242249 to AA242264 and AAF64644 to AAF64650 represent
 CC sequences used in the exemplification of the present invention.
 CC
 SQ Sequence 149 AA:
 Query Match 5.3%; Score 10; DB 21; Length 149;
 Best Local Similarity 100.0%; Pred. No. 0.028;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 81 VLAFCNOFG 90
 |||||||||
 DB 103 vlaifpncgfg 112
 RESULT 12
 AAB18915
 ID AAB18915 standard; Protein; 209 AA.
 XX
 AC AAB18915;
 XX
 DT 08-FEB-2001 (first entry)
 XX
 DE A novel polypeptide designated PRO1785.
 XX
 KW Secreted protein; transmembrane protein; PRO1484; PRO4334; PRO1122;
 KW PRO1889; PRO1890; PRO1887; PRO1785; PRO4353; PRO4405; PRO4356;
 KW PRO4352; PRO4380; PRO4354; PRO4573; PRO4425; PRO590; PRO6030;
 KW PRO4424; PRO4422; PRO4430; PRO4499; tumour; obesity; diabetes;
 KW insulinemia; kidney disorder; Bergers disease; nephropathy;
 KW Schonlein-Henoch purpura; celliac disease; dermatitis herpetiformis;
 KW Crohns disease.
 XX
 OS Homo sapiens.
 XX
 FN
 XX
 FT Key Location/Qualifiers
 FT Peptide 1..31
 FT /note= "signal peptide"
 FT Misc-difference 118
 FT /note= "Asp encoded by CCA"
 XX
 PN W0200056889-A2.
 XX
 PD 28-SEP-2000.

XX 01-MAR-2000; 2000WO-US05601.
XX
XX 23-MAR-1999; 99US-0125774.
PR 23-MAR-1999; 98US-0125778.
PR 24-MAR-1999; 98US-0125828.
PR 31-MAR-1999; 98US-0127033.
PR 05-APR-1999; 98US-0127706.
PR 21-APR-1999; 98US-0130359.
PR 27-APR-1999; 98US-0131270.
PR 27-APR-1999; 98US-0131272.
PR 27-APR-1999; 98US-0131291.
PR 04-MAY-1999; 98US-0132371.
PR 04-MAY-1999; 98US-0132379.
PR 25-MAY-1999; 98US-0132383.
PR 08-JUN-1999; 98US-0135750.
PR 20-JUL-1999; 98US-0138166.
PR 03-AUG-1999; 98US-0144971.
PR 09-DEC-1999; 98US-0170262.
XX
XX (GETH) GENENTECH INC.
XX
XX Desnoyers L, Eaton DL, Goddard A, Godowski PJ, Gurney AL, Pan J;
PI Stewart TA, Watanabe CK, Wood WL, Zhang Z;
XX
XX WPI: 2000-628263/60.
DR N-PSDB: AAA96342.
XX
XX Novel secreted and transmembrane polypeptides useful for diagnosing
PT tumor in a mammal, for identifying agonists and antagonists of the
PT polypeptide and for therapeutic use
XX
XX Claim 12; Fig 14; 222pp: English.
XX
XX The present sequence represents a secreted or transmembrane polypeptide.
CC The specification describes polypeptides designated PRO1484, PRO4334,
CC PRO1122, PRO1889, PRO1887, PRO1785, PRO4353, PRO4357, PRO4405,
CC PRO4356, PRO4352, PRO4380, PRO4354, PRO4408, PRO5737, PRO4425, PRO5990,
CC PRO6030, PRO4424, PRO4422, PRO4430 and PRO4499. PRO1889 polypeptide is
CC useful for diagnosing tumor in a mammal. The polypeptides, their
CC agonists and antagonists are useful creating a condition associated with
CC expression or activity of the polypeptide. Conditions treated include
CC obesity, diabetes or hyper-or hypo-insulinemia. The polypeptides are
CC capable of inducing proliferation of mammalian kidney mesangial cells
CC and are therefore useful for treating kidney disorders associated with
CC decreased mesangial cell function such as Bergers disease or other
CC nephropathies associated with Schonlein-Henoch purpura, celiac disease,
CC dermatitis herpetiformis or Crohns disease. The nucleic acids may be used
CC to generate transgenic animals for use in development and screening of
CC therapeutically useful reagents and also for chromosome identification
CC and tissue typing.
XX
XX Sequence 209 AA:
SQ

Query Match 5.3%; Score 10; DB 21; Length 209;
Best Local Similarity 100.0%; Pred. No. 0.037;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 81 VLAFCPCNFG 90
DB 103 VLAFCPCNFG 112

RESULT 13
AAB24484
ID AAB24484 standard; Protein; 209 AA.
XX
XX AAB24484;
AC
XX
XX 20-NOV-2000 (first entry)
XX

DE Human secreted protein sequence encoded by gene 16 SEQ ID NO:109.
XX
XX Human; secreted protein; cytostatic; antianemic; antidiabetic;
KW antinflammatory; ophthalmological; antirheumatic; antiarthritic;
KW antipruritic; antidiabetic; cardiatic; anti-HIV; neurologic;
KW neoprotective; antimicrobial; antiparkinsonian; cancer;
KW immune system disorder; angiogenesis; hyperproliferative disorder;
KW cardiovascular disorder; apoptosis; neurological disease;
KW infectious disease; wound healing; chromosome 5.
XX
XX Homo sapiens.
OS
XX WO200035937-A1.
XX
XX 22-JUN-2000.
XX
XX 16-DEC-1999; 99WO-US29950.
XX
XX 17-DEC-1998; 98US-0112809.
PR 18-DEC-1998; 98US-0113006.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Ruben SM, Ebner R, Rosen CA, Endress GA, Soppet DR, Ni J;
PI Duan DR, Moore PA, Shi Y, Lafleur DW, Olsen HS, Florence K;
XX
XX WPI: 2000-431566/37.
DR N-PSDB: AAA78428.
XX
XX Forty seven human nucleic acids encoding secreted proteins, useful in
PT the treatment, prevention and diagnosis of cancers, disorders of the
PT immune system, angiogenesis disorders, neurological diseases and
PT hyperproliferative disorders
XX
XX Claim 11; Page 523-524; 562pp: English.
XX
XX The polynucleotide sequence given in AAA78381 to AAA78432 encode the
CC human secreted proteins given in AAB24437 to AAB24604. Human secreted
CC proteins have activities based on the tissues and cells the genes are
CC expressed in. Examples of activities include: cytostatic; antianemic;
CC antidiabetic; antinflammatory; ophthalmological; antirheumatic;
CC antiarthritic; antipruritic; antidiabetic; cardiatic; anti-HIV;
CC neurologic; neoprotective; antimicrobial and antiparkinsonian.
CC Human secreted protein polynucleotides, polypeptides, antagonists and/or
CC agonists may be useful in treating, preventing, and/or diagnosing other
CC disorders, disorders, and/or conditions such as: (a) cancers; (b)
CC disorders of the immune system; (c) angiogenesis disorders; (d)
CC hyperproliferative disorders; (e) cardiovascular disorders; (f) diseases
CC associated with increase apoptosis; (g) neurological diseases; and
CC (h) infectious diseases. They are also used to promote wound healing.
CC AAA78372 to AAA78380 and AAB24436 represent sequences used in the
CC exemplification of the present invention.
XX
XX Sequence 209 AA:
SQ

Query Match 5.3%; Score 10; DB 21; Length 209;
Best Local Similarity 100.0%; Pred. No. 0.037;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 81 VLAFCPCNFG 90
DB 103 VLAFCPCNFG 112

RESULT 14
AAU29258
ID AAU29258 standard; Protein; 209 AA.
XX
XX AAU29258;
AC
XX
XX 18-DEC-2001 (first entry)
XX

DE Human PRO polypeptide sequence #235.
 XX
 KW PRO polypeptide; mammal; tumour; cancer; human; cattle; horse; sheep;
 KW dog; cat; pig; goat; rabbit; tumour necrosis factor alpha; TNF-alpha;
 KW blood; chondrocyte cell; cell proliferation; cell differentiation; colon;
 KW adrenal; lung; breast; prostate; rectum; cervix; liver; genetic disorder.
 OS Homo sapiens.
 XX
 PN WO200168848-A2.
 XX
 PD 20-SEP-2001.
 XX
 PF 28-FEB-2001; 2001WO-US06520.
 XX
 PR 01-MAR-2000; 2000WO-US05601.
 PR 02-MAR-2000; 2000WO-US05841.
 PR 03-MAR-2000; 2000US-187202P.
 PR 06-MAR-2000; 2000US-186968P.
 PR 14-MAR-2000; 2000US-189320P.
 PR 14-MAR-2000; 2000US-189328P.
 PR 15-MAR-2000; 2000WO-US06884.
 PR 21-MAR-2000; 2000US-190828P.
 PR 21-MAR-2000; 2000US-191007P.
 PR 21-MAR-2000; 2000US-191048P.
 PR 21-MAR-2000; 2000US-191314P.
 PR 28-MAR-2000; 2000US-192655P.
 PR 29-MAR-2000; 2000US-193032P.
 PR 29-MAR-2000; 2000US-193053P.
 PR 30-MAR-2000; 2000WO-US08439.
 PR 04-APR-2000; 2000US-194449P.
 PR 04-APR-2000; 2000US-194647P.
 PR 11-APR-2000; 2000US-195975P.
 PR 11-APR-2000; 2000US-196000P.
 PR 11-APR-2000; 2000US-196187P.
 PR 11-APR-2000; 2000US-196680P.
 PR 11-APR-2000; 2000US-196820P.
 PR 18-APR-2000; 2000US-198121P.
 PR 18-APR-2000; 2000US-198585P.
 PR 25-APR-2000; 2000US-199397P.
 PR 25-APR-2000; 2000US-199550P.
 PR 03-MAY-2000; 2000US-199654P.
 PR 17-MAY-2000; 2000WO-US13705.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 30-MAY-2000; 2000WO-US14941.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 05-JUN-2000; 2000US-209832P.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 22-AUG-2000; 2000US-0644848.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 08-NOV-2000; 2000WO-US30952.
 PR 01-DEC-2000; 2000WO-US32678.
 PR 20-DEC-2000; 2000WO-US34956.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2001-602746/68.
 DR N-PSDB; AAS46159.
 XX
 PT Novel nucleic acids encoding PRO polypeptides, used to diagnose the
 PT presence of tumours, such as prostate and breast tumours, in mammals and
 PT to screen for modulators of the compounds -
 XX
 PS Claim 11; Fig 470; 774pp; English.
 XX
 CC Sequences AAN29024-AU029328 represent PRO polypeptides of the invention.
 CC The PRO polypeptides and their associated nucleic acids can be used to
 CC detect the presence of a tumour in a mammal by comparing the level of
 CC expression of a PRO polypeptide in a test sample of cells from the animal

CC and a control sample of normal cells, whereby a higher level of
 CC expression in the test sample indicates the presence of a tumour in the
 CC mammal. Mammals include dogs, cats, cattle, horses, sheep, pigs, goats
 CC and rabbits but are preferably human. The polypeptides can be used to
 CC stimulate tumour necrosis factor (TNF) alpha release from human blood,
 CC when contacted with it. A specific polypeptide can be used to stimulate
 CC the proliferation or differentiation of chondrocyte cells. The PRO
 CC proteins can be used to determine the presence of tumours and also
 CC susceptibility to tumour development, particularly adrenal, lung, colon,
 CC breast, prostate, rectal, cervical, or liver tumours, in mammalian
 CC subjects. The oligonucleotide probes specific for the PRO nucleic acids
 CC can be used for genetic analysis of individuals with genetic disorders.
 CC
 SQ Sequence 209 AA;
 XX
 QY 81 VLAFCNQFG 90
 Db 103 vlafcngf 112
 Query Match 5.3%; Score 10; DB 22; Length 209;
 Best Local Similarity 100.0%; Pred. NO. 0.037;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 RESULT 15
 ID AAM39735 standard; Protein; 209 AA.
 XX
 AC AAM39735;
 XX
 DT 22-OCT-2001 (first entry)
 XX
 DE Human polypeptide SEQ ID NO 2880.
 XX
 KW Human; noctropic; immunosuppressant; cytosolic; gene therapy; cancer;
 KW peripheral nervous system; neuropathy; central nervous system; CNS;
 KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
 KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; Chemotactic;
 KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
 KW leukaemia.
 XX
 OS Homo sapiens.
 XX
 PN WO200153312-A1.
 XX
 PD 26-JUL-2001.
 XX
 PF 26-DEC-2000; 2000WO-US34263.
 XX
 PR 21-JAN-2000; 2000US-0488725.
 PR 25-APR-2000; 2000US-0552317.
 PR 09-JUL-2000; 2000US-0598042.
 PR 19-JUL-2000; 2000US-0620312.
 PR 03-AUG-2000; 2000US-0653450.
 PR 14-SEP-2000; 2000US-0662191.
 PR 19-OCT-2000; 2000US-0693036.
 PR 29-NOV-2000; 2000US-0727344.
 XX
 PA (HYSE-) HYSEQ INC.
 XX
 PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
 PI Wang J, Wang Z, Wehrman T, Xu C, Xue AD, Yang Y, Zhang J;
 PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
 XX
 DR WPI; 2001-442253/47.
 DR N-PSDB; AAT58891.
 XX
 PT Novel nucleic acids and polypeptides, useful for treating disorders
 PT such as central nervous system injuries -
 XX
 PS Example 4; SEQ ID NO 2880; 10078pp; English.
 XX

CC The invention relates to human nucleic acids (AA157798-AA161369) and
CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC immunosuppressant and cytosstatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the printed
CC specification.
XX

Sequence 209 AA:

Query Match

Best Local Similarity 5.3%; Score 10; DB 22; Length 209;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 81 VLAFCNCRG 90
|||
Db 103 vlaifpcngfg 112

Search completed: August 23, 2002, 14:40:53
Job time: 140 sec

